Nordic Pharma to Present Data on Lacrifill Canaliocular Gel, a Novel Therapy for Dry Eye, at ASCRS

Nordic Pharma will be presenting data on Lacrifill Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston, on April 5-8, 2024. Lacrifill Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

“These are truly exciting times for Nordic Pharma as we near the U.S. launch of Lacrifill Canalicular Gel, a key milestone in our global expansion strategy," Charlotte Phelps, CEO of Nordic Pharma, said in a company news release. “The recent acquisition of Visant Medical along with Amring Pharmaceuticals becoming Nordic Pharma Inc. has increased our internal know-how and assets. And with our strong U.S. leadership team and the invaluable support of our Medical Advisory Board, I firmly believe that Nordic Pharma is well-positioned to thrive as a new specialty ophthalmic player and enhance patient care by introducing this novel therapy for dry eye."

"As chairperson of the Lacrifill U.S. Medical Advisory Board, I am excited about the potential of employing a cross-linked hyaluronic lacrimal filler to optimally occlude the canalicular system to maximize tear film preservation in patients with dry eye symptoms," said Eric D. Donnenfeld, MD.

ASCRS attendees are invited to stop by booth #1245 to learn more about the Lacrifill Canalicular Gel. Attendees will also have the opportunity to be among the first eye care professionals to place orders. Lacrifill Canalicular Gel will be featured at various Refractive and Cornea Day sessions throughout the meeting, including the “LACRIFILL: A Paradigm Shift in Dry Eye Intervention” panel, which will be held on Saturday, April 6, 2024 and will include the distinguished faculty of Eric Donnenfeld, MD; Preeya Gupta, MD; Darrell White, MD; and Kevin J. Corcoran, COE, CPC, CPMA, FNAO and the Principal of Corcoran & Corcoran.

Mark Packer, MD, FACS, CPI, who will be moderating the panel said, “As a lacrimal filler, cross-linked hyaluronic acid provides a new approach to preservation of the tear film, protecting and conforming to delicate tissues while blocking outflow. Lacrifill Canalicular Gel transforms treatment of the ocular surface, with demonstrated safety and effectiveness for both signs and symptoms of dry eye.”

For more information and ordering details for Lacrifill Canalicular Gel visit lacrifill.com.